The prevalence of chronic kidney disease in South Africa - limitations of studies comparing prevalence with sub-Saharan Africa, Africa, and globally

Abstract

Background Chronic kidney disease (CKD) is a globally significant non-communicable disorder. CKD prevalence varies between countries and within a country. We compared the prevalence rates of CKD in South Africa with sub-Saharan Africa, Africa, and globally. Methods We registered a systematic review with the International Prospective Register of Systematic Reviews for prevalence studies reporting CKD stages III-V from 2013 to 2021. The analysis sought to explain any significant differences in prevalence rates. The R statistical package was used for data analysis. Comparisons included measures of effect size due to the large sample sizes analysed. We also compared sex differences in prevalence rates, common aetiologies, and type of study methodologies employed. Results Eight studies were analysed, with two from each region. The matched prevalence rates of CKD between the various regions and South Africa showed significant differences, except for one comparison between South Africa and an African study [p = 0.09 (95% CI − 0.04–0.01)]. Both sub-Saharan African studies had a higher prevalence than South Africa. One study in Africa had a higher prevalence, while the other had a lower prevalence, whilst one Global study had a higher prevalence, and the other had a lower prevalence compared to South Africa. The statistical differences analysed using the Cramer’s V test were substantially less than 0.1. Thus, differences in comparisons were largely due to differences in sample sizes rather than actual differences. Conclusion Variable prevalence rates between regions included disparities in sample size, definitions of CKD, lack of chronicity testing and heterogeneous laboratory estimations of eGFR. Improved consistency and enhanced methods for diagnosing and comparing CKD prevalence are essential.

Clinical-epidemiological characterization of patients submitted to hemodialysis according to the national kidney foundation, the kidney disease outcomes quality initiative – KDOQI in a hemodialysis reference center in the metropolitan region of São Paulo, Brazil

“…It is noteworthy that the findings of Hariparshad et al, 29 show that Varying prevalence rates across regions have included disparities in sample size, definitions of CKD, lack of testing for chronicity, and heterogeneous laboratory estimates of eGFR , and better consistency and improved methods for diagnosing and comparing CKD prevalence are essential.…”

A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy

“…Chronic kidney disease is a progressive medical condition that affects approximately 10% of the global population, with over 800 million reported cases worldwide ( 1 ). The International Society of Nephrology Global Health Atlas survey for Africa has estimated the prevalence of this condition to be similarly high in South Africa, especially aggravated/exacerbated by socioeconomic inequalities ( 2 ). Older individuals, including people with other disease conditions such as diabetes mellitus, hypertension, and human immunodeficiency virus (HIV), present with the greatest burden of kidney disease ( 3 ).…”

Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria

“…The burden of ESKD and the demand for haemodialysis are increasing. In Sub-Saharan countries of Africa, the prevalence of chronic renal diseases is between 10.7% and 13.9% [ 5 ]. In Nigeria, 20.4% of 14,253 screened participants had chronic kidney disease [ 6 ].…”